Biogen Inc.: New Data at ECTRIMS 2022 Highlight Biogen's Commitment to Advancing Individualized Disease Management for People Living with MS
Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY (diroximel fumarate) consistent with previous
Nordrhein Westfalen United Kingdom Maha Radhakrishnan Charles Weissmann Walter Gilbert Heinz Schaller
Source: finanznachrichten.de